News & Publications
Abstracts
Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting
Cost-Effectiveness of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Disease
Gourzoulidis G, Koulentaki M, Koumarianou A, Samantas E, Androulakis N, Xynogalos S, et al Value in Health. 2020;23:S439.
Budget IMPACT Analysis of Empagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and High Risk or Established Atherosclerotic Cardiovascular Disease in Greece
Tzanetakos C, Gourzoulidis G, Papanas N, Papageorgiou G, Karpouzos G, Saloustros I, et al. Value in Health. 2020;23:S512. https://doi.org/10.1016/j.jval.2020.08.635
Cost Comparison of Low Dose Dabigatran over Other NOVEL ORAL Anticoagulants for the Treatment of Patients with NON-Valvular Atrial Fibrillation WHO HAD NOT Previously Taken an ORAL Anticoagulant in Greece
Gourzoulidis G, Delli E, Wammes K, Papageorgiou G, Kourlaba G. Value in Health. 2020;23:S496. https://doi.org/10.1016/j.jval.2020.08.544
Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-Small-Cell-Lung Cancer in Greece
Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Almond C, Tzanetakos C, et al. Value in Health. 2020;23:S442. https://doi.org/10.1016/j.jval.2020.08.244
Budget IMPACT Analysis of Trifluridine/Tipiracil (FTD/TPI) As a Third-LINE Treatment of Metastatic Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction, Among Patients WHO Have Received at Least Two PRIOR Therapies for Metastatic Dise
Gourzoulidis G, Koulentaki M, Koumarianou A, Samantas E, Androulakis N, Xynogalos S, et al. Value in Health. 2020;23:S431-S2. https://doi.org/10.1016/j.jval.2020.08.194
The Cost-Effectiveness of Liposomal Irinotecan and 5-Fluorouracil (5-FU)/ Leucovorin (LV) for the Treatment of Patients with Metastatic Adenocarcinoma of Pancreas WHO Have Progressed Following the Use of Gemcitabine-Related Therapies in Greece
Gourzoulidis G, Stefanou G, Koulentaki M, Beletsi A, Boukovinas I, Karamouzis M, et al Value in Health. 2020;23:S442. https://doi.org/10.1016/j.jval.2020.08.245
Cost-minimization Analysis of Damoctocog Alfa Pegol in severe Hemophilia A in Greece
Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G Value in Health. 2019;22:S848. https://doi.org/10.1016/j.jval.2019.09.2371
Cost-effectiveness analysis of Tofacitinib for the treatment of moderate to severe active uclerative colitis in Greece
Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Kourlaba G. Value in Health. 2019;22:S619-S20. https://doi.org/10.1016/j.jval.2019.09.1142
Real-World Data for Non Small Cell Lung Cancer patients with positive EGFR Mutation in Greece: Preliminary Results from a registry
Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S435. https://doi.org/10.1016/j.jval.2019.09.199
Budget Impact Analysis of Damoctocog Alfa Pegol in Severe Hemophilia A in Greece
Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G. Value in Health. 2019;22:S844.
Real-World Data of Nivolumab in Non Small Cell Lung Cancer patients in Greece
Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S435-S6. https://doi.org/10.1016/j.jval.2019.09.202
Budget Impact Analysis of a Biosynthetic MESH for abdominal Wall Hernia repair in Complex Hernias in Greece
Vellopoulou K, Apostolidis S, Chatzimavroudis G, Chrisoheris P, Christodoulidis G, Ntatsis K, et al. Value in Health. 2019;22:S673. https://doi.org/10.1016/j.jval.2019.09.1436
Incidence and Cost of Bleeding events requiring Hospitalization in patients with Atrial Fibrillation treated with Acenocoumarol, in Greece
Kourlaba G, Stefanou G, Tsalamandris S, Oikonomou E, Papageorgiou G, Nikas N, et al. Value in Health. 2019;22:S543. https://doi.org/10.1016/j.jval.2019.09.738
End-of-LIFE Cost for Lung Cancer Patients in Greece: A hospital-based retrospective study
Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S476. https://doi.org/10.1016/j.jval.2019.09.405
Does a standard Willingness-to-pay thereshold exist in Greece?
Tzanetakos C, Stefanou G, Gourzoulidis G. Value in Health. 2019;22:S772-S3. https://doi.org/10.1016/j.jval.2019.09.1963
COST-UTILITY ANALYSIS OF PEGASPARGASE FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN GREECE
Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G, Econcare LP, Athens, A, Greece, First Department of Pediatrics, National and Kapodistrian University of Athens, ’Aghia Sophia’ Children’s Hospital, Athens, Greece, Hematology and Lymphoma Department, Evangelismos General Hospital, Athens, Greece, SERVIER HELLAS Pharmaceuticals LTD, Athens, A1, Greece Value in Health. 2022;01:S101.
BUDGET IMPACT ANALYSIS OF PEGASPARGASE FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA IN GREECE
Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G Econcare LP, Athens, A1, Greece, First Department of Pediatrics, National and Kapodistrian University of Athens, ’Aghia Sophia’ Children’s Hospital, Athens, Greece, Hematology and Lymphoma Department, Evangelismos General Hospital, Athens, Greece, SERVIER HELLAS Pharmaceuticals LTD, Athens, A1, Greece. 2022;01:S48.
Patients' satisfaction, unmet needs and treatment benefits in moderate to severe psoriasis in Greece: results from a cross-sectional survey
Garyfallia Stefanou 1, Georgia Kourlaba 2, Eirinaios Vamvakousis 3, Soultana Koukopoulou 3, John Yfantopoulos 4. Ital J Dermatol Venerol. 2022 Jun 6. doi: 10.23736/S2784-8671.22.07258-9.
Prevalence of adult self-reported atopic dermatitis in Greece: results from a nationwide survey
Tel: (+30) 2169001701, 2121052769
info[at]econcare.gr